In June 2009 the U.S. Judicial Panel on Multidistrict Litigation denied a request to consolidate Reglan lawsuits in one federal district. The panel issued their order on June 3, 2009 stating that the centralization of 11 different Reglan lawsuits before one judge for pretrial coordination was not appropriate at this time.
The lawsuits filed against the makers of Reglan and the generic, Metoclopramide, claim that the manufacturers failed to adequately warn about the potential tardive dyskinesia side effects of Reglan associated with long term use.
In February 2009, the FDA required the addition of a "black box" warning about the risk of Tardive Dyskinesia associated with long-term or high dose Reglan use.
The panel was persuaded by the drug makers' assertions that consolidated proceedings were not necessary. The drug makers pointed to 20 years of Reglan litigation that includes over 70 lawsuits. According to the manufacturers about 80% of the lawsuits filed have been resolved.
No comments:
Post a Comment